NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $27.67 -0.42 (-1.50%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$28.18 +0.51 (+1.86%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$27.63▼$28.4650-Day Range$26.28▼$30.0452-Week Range$25.52▼$43.18Volume722,216 shsAverage Volume892,567 shsMarket Capitalization$1.40 billionP/E RatioN/ADividend YieldN/APrice Target$48.71Consensus RatingModerate Buy Company Overview AtriCure, Inc. is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF. The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques. In addition, AtriCure markets the LARIAT Suture Delivery Device for left atrial appendage closure to help reduce stroke risk in AF patients who are unable to tolerate long-term anticoagulation therapy. AtriCure continues to invest in R&D initiatives aimed at expanding its surgical and hybrid EP solutions, as well as digital platforms for intraoperative mapping and post-procedural monitoring. AtriCure operates internationally with sales and distribution channels across North America, Europe, Asia and select emerging markets. The company collaborates with leading cardiac centers, physician innovators and academic institutions to conduct clinical studies and training programs that support adoption of its technologies. Under the leadership of President and Chief Executive Officer Jonathan M. Cathcart, AtriCure has pursued strategic partnerships and targeted acquisitions to enhance its electrophysiology portfolio and drive long-term growth. The company remains committed to expanding access to safe, effective AF treatments and advancing the standard of care in cardiac surgery and electrophysiology.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 71% of companies evaluated by MarketBeat, and ranked 255th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAtriCure has a consensus price target of $48.71, representing about 76.1% upside from its current price of $27.67.Amount of Analyst CoverageAtriCure has only been the subject of 4 research reports in the past 90 days.Read more about AtriCure's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3,300.00% Earnings GrowthEarnings for AtriCure are expected to grow by 3,300.00% in the coming year, from $0.01 to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -276.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -276.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.11% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.52.Change versus previous monthShort interest in AtriCure has recently increased by 14.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.73 News SentimentAtriCure has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AtriCure this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,100.00 in company stock.Percentage Held by Insiders4.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesJushi (OTCMKTS:JUSHF) vs. AtriCure (NASDAQ:ATRC) Head to Head SurveyMay 28 at 3:40 AM | americanbankingnews.comAtriCure (NASDAQ:ATRC) Director Sells $85,950.00 in StockMay 25, 2026 | americanbankingnews.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 30 at 1:00 AM | Porter & Company (Ad)AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 24, 2026 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Director Karen Prange Sells 3,000 SharesMay 23, 2026 | insidertrades.comAtriCure Shareholders Approve Expanded Equity and Governance PlansMay 19, 2026 | tipranks.comPiper Sandler Sticks to Its Buy Rating for Atricure (ATRC)May 14, 2026 | theglobeandmail.comAtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $39.56 at the beginning of 2026. Since then, ATRC shares have decreased by 30.1% and is now trading at $27.67. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its earnings results on Tuesday, February, 17th. The medical device company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.10. The firm's revenue for the quarter was up 13.1% compared to the same quarter last year. Read the conference call transcript. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? Top institutional shareholders of AtriCure include Dimensional Fund Advisors LP (1.97%), Bank of America Corp DE (1.52%), First Light Asset Management LLC (1.44%) and WCM Investment Management LLC (0.71%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings2/17/2026Today5/30/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/10/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, ATRC's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,300Year Founded2000Price Target and Rating Average Price Target for AtriCure$48.71 High Price Target$55.00 Low Price Target$36.00 Potential Upside/Downside+76.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E Ratio2,767.00 P/E GrowthN/ANet Income-$11.45 million Net Margins-0.83% Pretax Margin-0.59% Return on Equity0.29% Return on Assets0.22% Debt Debt-to-Equity Ratio0.15 Current Ratio4.29 Quick Ratio3.18 Sales & Book Value Annual Sales$534.53 million Price / Sales2.62 Cash Flow$0.31 per share Price / Cash Flow89.75 Book Value$9.71 per share Price / Book2.85Miscellaneous Outstanding Shares50,640,000Free Float48,615,000Market Cap$1.40 billion OptionableOptionable Beta1.28 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ATRC) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredMusk takes on IranIranian drones have struck Amazon's data centers, with Microsoft, Google, Oracle, and Nvidia reportedly next o...Brownstone Research | SponsoredThe real reason Burry went darkMichael Burry - the man who made $725 million shorting the 2007 housing market - quietly deregistered Scion As...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
